Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Thomas M. Habermann discusses whether treatment of marginal zone lymphoma (MZL) should be different than that of follicular lymphoma. © 2019 Imedex, an HMP Company
Treatment for Marginal Zone Lymphoma: Should it be Different from Follicular Lymphoma?
